Church & Dwight
CHD
$96.74
+2.78%
Church & Dwight Co., Inc. is a leading consumer packaged goods company operating in the Household & Personal Products industry, best known as the global leader in baking soda production and the steward of the iconic Arm & Hammer brand. The company has successfully diversified its portfolio beyond its legacy product into a multi-brand platform encompassing laundry care, cat litter, oral care, deodorant, and vitamins, with its core brands—Arm & Hammer, OxiClean, Vitafusion, and TheraBreath—collectively driving approximately 70% of sales and profits. The current investor narrative centers on the company's ability to navigate a challenging consumer environment, with recent attention focused on its Q4 2025 earnings results, which showed modest revenue growth but a significant year-over-year decline in net income, raising questions about margin pressures and the integration of recent acquisitions like Touchland.…
CHD
Church & Dwight
$96.74
Investment Opinion: Should I buy CHD Today?
Rating: Hold. The core thesis is that CHD is a financially sound, defensive company currently facing a profitability headwind that makes its premium valuation difficult to justify for new money, though its strong fundamentals prevent a Sell recommendation.
The Hold rating is supported by four specific data points: 1) The forward P/E of 23.44x is a premium to many defensive peers, 2) Revenue growth has decelerated to 3.93% YoY in Q4 from stronger prior quarters, 3) Profitability is under clear pressure with net income down 24.2% YoY, and 4) The stock offers minimal implied upside to its recent 52-week high of $106.04, with technicals indicating a downtrend. However, robust TTM FCF of $1.093B and a solid ROE of 18.41% provide underlying support.
The two biggest risks are sustained margin compression and valuation de-rating. This Hold would upgrade to a Buy if the forward P/E compresses below 20x while growth stabilizes, or if Q1 2026 results show clear gross margin recovery above 46.5%. It would downgrade to a Sell if revenue growth turns negative or if net margin falls below 10%. Based on its PEG ratio of 1.02 and premium sector multiple, the stock is currently fairly valued to slightly overvalued relative to its near-term growth prospects.
Sign up to view all
CHD 12-Month Price Forecast
The outlook for CHD is one of stability with muted near-term upside. The company's strong cash generation and defensive portfolio are offset by clear profitability pressures that have shaken investor confidence, as seen in its year-long downtrend. The base case of range-bound trading is most likely, contingent on margins stabilizing. The stance would upgrade to bullish on clear evidence of gross margin recovery in the next quarterly report, supported by management commentary on pricing power. Conversely, another quarter of significant margin decline would warrant a shift to a bearish stance, as it would likely trigger the bear-case scenario of valuation compression.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Church & Dwight's 12-month outlook, with a consensus price target around $125.76 and implied upside of +30.0% versus the current price.
Average Target
$125.76
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$77 - $126
Analyst target range
Analyst coverage for CHD is limited, with only 5 analysts providing estimates, which is relatively low for a company of its market cap and suggests it may be under-followed by the broader institutional research community. The consensus leans neutral to cautiously optimistic, with recent ratings from major firms including Wells Fargo (Overweight), Jefferies (Buy), Morgan Stanley (Equal Weight), and Citigroup (Neutral), indicating a lack of strong conviction for a major breakout. The average revenue estimate for the upcoming period is $7.225 billion, with a tight range between $7.159 billion and $7.367 billion, reflecting moderate growth expectations and low forecast dispersion. The average EPS estimate is $4.78, bracketed by a low of $4.72 and a high of $4.90, implying stable but unspectacular bottom-line performance; the narrow target range suggests analysts have a high degree of agreement on the company's near-term fundamentals, but the limited coverage overall can lead to higher volatility and less efficient price discovery.
Bulls vs Bears: CHD Investment Factors
The evidence currently tilts bearish, primarily due to the severe margin compression witnessed in Q4 2025, which has eroded profitability despite modest top-line growth. The bull case rests on the company's defensive characteristics, strong cash flow, and solid balance sheet, which provide a floor. However, the bear case is strengthened by a premium valuation that appears misaligned with decelerating growth and earnings pressure. The single most important tension in the investment debate is whether CHD can successfully restore its profit margins through pricing, cost savings, or acquisition synergies to justify its elevated P/E multiple, or if continued margin erosion will trigger a further de-rating.
Bullish
- Strong Free Cash Flow Generation: The company generates robust free cash flow, with TTM FCF of $1.093 billion. This provides ample liquidity for shareholder returns, strategic acquisitions like Touchland, and debt servicing, underpinning financial resilience.
- Defensive Portfolio with Low Beta: CHD's beta of 0.482 indicates it is roughly 52% less volatile than the market. This defensive characteristic, combined with its portfolio of essential household and personal care brands, offers stability during economic uncertainty, as evidenced by its underperformance during the recent market rally.
- Solid Balance Sheet & ROE: A debt-to-equity ratio of 0.55 shows moderate leverage, while an ROE of 18.41% demonstrates efficient capital allocation. This conservative financial structure provides flexibility for navigating margin pressures and funding growth.
- Analyst Consensus Points to Stable EPS: The average analyst EPS estimate for the upcoming period is $4.78, with a narrow range from $4.72 to $4.90. This high degree of agreement suggests predictable, albeit modest, bottom-line performance and low earnings surprise risk.
Bearish
- Severe Margin Compression in Q4: Q4 2025 net income fell sharply to $143.5M from $189.2M YoY, and the gross margin contracted to 45.85% from 47.45%. This indicates significant pressure from input costs or competition, directly threatening earnings quality despite 3.93% revenue growth.
- Premium Valuation with Slowing Growth: A trailing P/E of 27.62x and forward P/E of 23.44x command a premium relative to the defensive sector. With revenue growth decelerating from Q1's 8.3% sequential growth to Q4's 3.93% YoY, the valuation appears rich for the growth profile, as reflected in a PEG ratio of 1.02.
- Persistent Underperformance vs. Market: The stock is down 5.53% over the past year and 6.53% over three months, significantly underperforming the S&P 500 by -32.57% and -19.13%, respectively. This technical downtrend reflects a loss of investor confidence and momentum.
- Limited Analyst Coverage & Neutral Sentiment: Only 5 analysts cover the stock, suggesting it may be under-followed. The consensus is neutral to cautious (e.g., Citi Neutral, Morgan Stanley Equal Weight), indicating a lack of strong conviction for a major re-rating or breakout.
CHD Technical Analysis
The stock is in a clear downtrend from its recent highs, having declined 5.53% over the past year and 6.53% over the last three months, significantly underperforming the S&P 500, which gained 27.04% and 12.6% over the same periods, respectively. Currently trading at $94.12, the price sits approximately 11.2% below its 52-week high of $106.04 and 15.7% above its 52-week low of $81.33, positioning it in the lower-middle portion of its annual range, suggesting a loss of momentum but not yet at deeply oversold levels. The 1-month price change of +0.63% indicates a slight stabilization or minor bounce from the March lows, yet this short-term uptick is weak and occurs within the context of a longer-term decline, signaling potential consolidation rather than a definitive reversal. The stock exhibits low market-correlated volatility with a beta of 0.482, meaning it is roughly 52% less volatile than the broader market, which has contributed to its defensive underperformance during the recent equity rally. Key technical support is firmly established at the 52-week low of $81.33, while immediate resistance lies at the recent high near $106.04; a sustained break above the $100-$101 level would be needed to challenge the downtrend, whereas a breakdown below $93 could accelerate a test of the $81 support zone.
Beta
0.47
0.47x market volatility
Max Drawdown
-18.1%
Largest decline past year
52-Week Range
$81-$106
Price range past year
Annual Return
-2.3%
Cumulative gain past year
| Period | CHD Return | S&P 500 |
|---|---|---|
| 1m | +1.9% | -0.0% |
| 3m | -3.9% | +8.7% |
| 6m | +14.5% | +8.0% |
| 1y | -2.3% | +23.1% |
| ytd | +17.1% | +8.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CHD Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 sales of $1.644 billion representing a 3.93% year-over-year increase; however, this growth has decelerated from the stronger performance seen in earlier quarters of fiscal 2025, such as Q1's 8.3% sequential growth from Q4 2024. The company remains profitable with a trailing twelve-month net margin of 11.88%, but profitability has come under pressure, as evidenced by Q4 2025 net income of $143.5 million declining sharply from $189.2 million in the year-ago quarter, and the quarterly gross margin of 45.85% contracting from 47.45% in Q4 2024. This margin compression, alongside a quarterly operating margin of 16.17%, suggests rising input costs or competitive pressures are impacting earnings quality despite stable top-line growth. The balance sheet is conservatively managed with a debt-to-equity ratio of 0.55, indicating moderate leverage, and a current ratio of 1.07 providing adequate short-term liquidity. The company generates robust free cash flow, with TTM FCF of $1.093 billion, supporting shareholder returns and strategic investments, while a return on equity of 18.41% demonstrates efficient use of shareholder capital despite the recent earnings volatility.
Quarterly Revenue
$1.6B
2025-12
Revenue YoY Growth
+0.03%
YoY Comparison
Gross Margin
+0.45%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CHD Overvalued?
Given the company's consistent profitability, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E stands at 27.62x, while the forward P/E is lower at 23.44x, indicating the market anticipates earnings growth and a recovery from the recent profit dip. Compared to the Consumer Defensive sector, which often trades at a lower multiple, CHD's premium P/E suggests the market is pricing in the stability of its branded portfolio and its market-leading positions. Historically, the stock's own P/E has fluctuated significantly, ranging from a low in the mid-20s to highs above 37x over the past few years; the current trailing multiple of 27.62x sits near the middle of this historical band, suggesting the stock is neither excessively cheap nor expensive based on its own history. The forward P/E discount to the trailing multiple implies analysts expect earnings to rebound, but the stock's valuation remains rich relative to its near-term growth prospects, as reflected in a PEG ratio of 1.02, indicating it is fairly valued relative to its expected growth rate.
PE
27.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -85x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks stem primarily from recent margin deterioration. The Q4 2025 gross margin contraction of 160 basis points (from 47.45% to 45.85%) and the 24.2% YoY decline in net income highlight vulnerability to input cost inflation and competitive pricing. While the debt-to-equity ratio of 0.55 is manageable, the company's reliance on brand strength to pass on costs is being tested. Furthermore, approximately 70% of sales and profits are concentrated in its core brands (Arm & Hammer, OxiClean, etc.), creating revenue concentration risk if any major brand falters.
Market & Competitive Risks are elevated by CHD's valuation premium. Trading at a forward P/E of 23.44x, the stock is priced for stability and growth in a sector that often trades at lower multiples. This creates compression risk if earnings disappoint or if investor sentiment shifts away from defensive, slower-growth names. The stock's low beta of 0.482, while defensive, has caused it to significantly lag the market rally, raising the risk of continued sector rotation out of underperformers. Intense competition in household and personal care from larger peers could further pressure pricing and market share.
Worst-Case Scenario involves a failure to arrest margin decline, leading to consecutive earnings misses and analyst downgrades. This could be exacerbated by a recessionary consumer pullback or a failed integration of the Touchland acquisition. Such a scenario would likely compress the P/E multiple toward its historical lower range and drive the stock price to retest its 52-week low of $81.33. From the current price of $94.12, this represents a realistic downside of approximately -13.6%. A breach of that support could trigger a steeper decline, potentially matching the stock's maximum drawdown of -18.1% observed recently.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: Continued gross margin compression, as seen in Q4 (down to 45.85%), which directly threatens earnings. 2) Valuation Risk: The stock's premium multiple could compress if growth slows further or margins don't recover, leading to price depreciation. 3) Competitive/Market Risk: Intense competition in its categories could limit pricing power, and its low beta (0.482) means it may continue to lag in a strong bull market. 4) Execution Risk: Challenges in integrating recent acquisitions like Touchland could lead to write-downs or diverted management focus.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $92 and $102, assuming margins stabilize and the company meets the consensus EPS of $4.78. The Bull Case (25% probability) targets $106 to $115, driven by successful margin restoration and multiple expansion. The Bear Case (15% probability) warns of a drop to the $81-$88 range if margin erosion continues, triggering a valuation de-rating. The base case is most likely, hinging on the critical assumption that the Q4 margin decline was a trough and not the start of a sustained downtrend.
CHD appears fairly valued to slightly overvalued. Its forward P/E of 23.44x is at a premium to many consumer defensive peers, pricing in stability and modest growth. However, with a PEG ratio of 1.02, it is priced almost exactly in line with its expected growth rate. Compared to its own history, the trailing P/E of 27.62x sits in the middle of its historical range, suggesting neither bargain nor extreme excess. The valuation implies the market expects the company to successfully navigate and recover from its current margin challenges; failure to do so would likely make the stock overvalued.
CHD is not a compelling buy at current levels for most investors. While it possesses strong fundamentals like a robust balance sheet (D/E of 0.55) and excellent free cash flow ($1.093B TTM), its premium forward P/E of 23.44x is difficult to justify amid clear margin pressure, with Q4 net income down 24.2% YoY. The stock has significantly underperformed the market, and the consensus analyst view is neutral. It could be a good buy for a very patient, defensive investor only if acquired at a lower price, such as near its 52-week low of $81.33, which would offer a better margin of safety.
CHD is primarily suitable for a long-term investment horizon of 3-5 years. Its low beta and defensive nature make it a poor candidate for short-term trading, as it lacks the volatility and momentum typically sought. As a long-term holding, it offers stability, reliable cash flow to fund dividends (current yield 1.41%), and the potential for steady, if unspectacular, capital appreciation as it works through margin cycles. The current profitability headwinds may take several quarters to resolve, further supporting a longer holding period to realize the investment thesis.